Immuron Limited – American Depositary Shares (NASDAQ:IMRN) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Immuron Limited – American Depositary Shares (NASDAQ:IMRN) from a buy rating to a hold rating in a research note published on Wednesday, April 4th.

According to Zacks, “Immuron Limited is a bio pharmaceutical Microbiome company. It focused on oral immunotherapy using polyclonal antibody products for humans. The company is involved in developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis. Immuron Limited is based in Armadale, Australia. “

How to Become a New Pot Stock Millionaire

IMRN has been the subject of a number of other reports. HC Wainwright reissued a buy rating and issued a $15.00 target price on shares of Immuron Limited – American Depositary Shares in a research note on Thursday, February 1st. ValuEngine cut Immuron Limited – American Depositary Shares from a buy rating to a hold rating in a research report on Monday, April 2nd.

NASDAQ IMRN traded down $0.01 on Wednesday, reaching $11.00. The company had a trading volume of 1,165 shares, compared to its average volume of 15,130. Immuron Limited – American Depositary Shares has a 52 week low of $4.47 and a 52 week high of $16.70.

TRADEMARK VIOLATION NOTICE: This article was first published by Macon Daily and is the property of of Macon Daily. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://macondaily.com/2018/04/12/immuron-limited-american-depositary-shares-imrn-lowered-to-hold-at-zacks-investment-research-updated.html.

About Immuron Limited – American Depositary Shares

Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.

Get a free copy of the Zacks research report on Immuron Limited – American Depositary Shares (IMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Immuron Limited - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Limited - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply